SEC Tracker
Get the app

Stoke Therapeutics STOK

M Kaye Edward (Director) plans to sell 42,350 STOK shares, about $588,665

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: May 20, 2024
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Previously Exercised Stock Options; Restricted Stock Units
  4. 10b5-1 plan adopted: Dec 26, 2023

All of M Kaye Edward's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 39,686 shares at $15.39 on May 20, 2024 · Form 4
  • Sold 2,664 shares at $16.05 on May 20, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Stoke Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  2. Mersana Therapeutics MRSN
  3. Evolus EOLS public float $560M, Jun 30, 2025
  4. Xencor XNCR public float $556M, Jun 30, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.